The Exploration of Peptide Biomarkers in Malignant Pleural Effusion of Lung Cancer Using Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry.

PubWeight™: 0.75‹?›

🔗 View Article (PMID 28386154)

Published in Dis Markers on March 13, 2017

Authors

Jing Xu1, Bin Xu2, Chuanhao Tang1, Xiaoyan Li1, Haifeng Qin1, Weixia Wang1, Hong Wang1, Zhongyuan Wang3, Liangliang Li1, Zhihua Li4, Hongjun Gao1, Kun He2, Xiaoqing Liu1

Author Affiliations

1: Department of Pulmonary Oncology, 307 Hospital, PLA, Beijing, China.
2: National Center of Biomedical Analysis, Beijing, China.
3: Department of Tuberculosis, 309 Hospital, PLA, Beijing, China.
4: Department of Oncology, General Hospital of the PLA Rocket Force, Beijing, China.

Articles cited by this

Management of a malignant pleural effusion: British Thoracic Society Pleural Disease Guideline 2010. Thorax (2010) 2.60

Proteomic analysis of exosomes isolated from human malignant pleural effusions. Am J Respir Cell Mol Biol (2004) 2.44

The malignant pleural effusion. A review of cytopathologic diagnoses of 584 specimens from 472 consecutive patients. Cancer (1985) 1.97

Comparison of needle biopsy with cytologic analysis for the evaluation of pleural effusion: analysis of 414 cases. Mayo Clin Proc (1985) 1.86

Detection of EGFR mutations in plasma DNA from lung cancer patients by mass spectrometry genotyping is predictive of tumor EGFR status and response to EGFR inhibitors. Lung Cancer (2010) 1.43

Pleural effusion. Postgrad Med J (2005) 1.31

Diagnostic value of CYFRA 21-1, CEA, CA 19-9, CA 15-3, and CA 125 assays in pleural effusions: analysis of 116 cases and review of the literature. Oncologist (2005) 1.20

Diagnostic value of carcinoembryonic antigen in malignant pleural effusion: a meta-analysis. Respirology (2008) 1.17

MALDI mass spectrometry for direct tissue analysis: a new tool for biomarker discovery. J Proteome Res (2005) 1.14

Angiogenetic biomarkers in non-small cell lung cancer with malignant pleural effusion: correlations with patient survival and pleural effusion control. Lung Cancer (2009) 1.00

Comprehensive proteome analysis of malignant pleural effusion for lung cancer biomarker discovery by using multidimensional protein identification technology. J Proteome Res (2011) 0.95

Differential proteome profiling of pleural effusions from lung cancer and benign inflammatory disease patients. Biochim Biophys Acta (2012) 0.93

Malignant effusions: from diagnosis to biology. Diagn Cytopathol (2004) 0.93

Diagnostic value of tumor markers in lung adenocarcinoma-associated cytologically negative pleural effusions. Cancer Cytopathol (2013) 0.90

In-depth proteomic analysis of six types of exudative pleural effusions for nonsmall cell lung cancer biomarker discovery. Mol Cell Proteomics (2015) 0.88

Malignant effusions: diagnostic evaluation and therapeutic strategy. Curr Probl Cancer (1981) 0.87

Analysis of diagnostic value of cytological smear method versus cell block method in body fluid cytology: study of 150 cases. Ethiop J Health Sci (2014) 0.85

Lung surfactant protein-A and carcinoembryonic antigen in pleural effusions due to lung adenocarcinoma and malignant mesothelioma. Eur Respir J (1995) 0.84

Proteomic analysis of pleural effusion from lung adenocarcinoma patients by shotgun strategy. Clin Transl Oncol (2013) 0.80

[Preliminary study of MALDI-TOF mass spectrometry-based screening of patients with the NSCLC serum-specific peptides]. Zhongguo Fei Ai Za Zhi (2013) 0.78

Diagnosing malignant pleural effusions: how do we compare? N Z Med J (2013) 0.78

Experience with closed needle biopsy and pleural fluid cytology in the diagnosis of malignant pleural effusions in Yaounde, Cameroon. East Afr Med J (1995) 0.78

Classification of Epidermal Growth Factor Receptor Gene Mutation Status Using Serum Proteomic Profiling Predicts Tumor Response in Patients with Stage IIIB or IV Non-Small-Cell Lung Cancer. PLoS One (2015) 0.77